Details

Autor(en) / Beteiligte

• Kahveci, Hasan
• Tayman, Cüneyt
• Laloğlu, Fuat
• Kavas, Nazan
• Ciftel, Murat
• Yılmaz, Osman
• Laloğlu, Esra
• Erdil, Abdulah
• Aksoy, Hülya
• Aydemir, Salih

Titel

Relationship Between Hemodynamically Significant Ductus Arteriosus and Ischemia-Modified Albumin in Premature Infants

Ist Teil von

• Indian journal of clinical biochemistry, 2016-04, Vol.31 (2), p.231-236

Ort / Verlag

New Delhi: Springer India

Erscheinungsjahr

2016

Quelle

Springer Online Journals【Remote access available】

Beschreibungen/Notizen

• Hemodynamically significant ductus arteriosus (hsPDA) may alter organ perfusion by interfering blood flow to the tissues. Therefore, in infants with hsPDA, hypoxia occurs in many tissues. In this study, we aimed to investigate the diagnostic significance of serum (ischemia-modified albumin) IMA levels as a screening tool for hsPDA, and its relation to the severity of the disease in the preterm neonates. For this purpose, seventy-two premature infants with gestation age <34 weeks were included in the study. Thirty premature infants with hsPDA were assigned as the study group and 42 premature infants without PDA were determined as the control group. Blood samples were collected before the treatment and 24 h after the treatment, and analyzed for IMA levels. IMA levels in the study group (1.26 ± 0.36 ABSU) were found to be significantly higher than control group (0.65 ± 0.12 ABSU) ( p  < 0.05). In infants with hsPDA, a positive correlation was found between IMA and PDA diameter (ρ = 0.876, p  = 0.022), and LA/Ao ratio (ρ = 0.863, p  = 0.014). The cut-off value of IMA for hsPDA was measured as 0.78 ABSU with 88.89 % sensitivity, and 90.24 % specificity, 85.71 % positive predictive, 92.5 % negative predictive value [area under the curve (AUC) = 0.96; p  < 0.001]. The mean IMA value of the infants with hsPDA before treatment was 1.26 ± 0.36 ABSU, and the mean IMA value of infants after medical treatment was 0.67 ± 0.27 ABSU ( p  = 0.03). We concluded that IMA can be used as a marker for the diagnosis and monitoring of a successful treatment of hsPDA.